7-Isobutyl-8-oxo-2-oxa-9-aza-bicyclo[10.2.2]hexadeca-1(15),12(16),13-triene-6,10-dicarboxylic acid 6-hydroxyamide 10-methylcarbamoylmethyl-amide (SL422) (Compound)

Pubchem:PUBCHEM:10344307
Id:be50ccd1-97ac-51d7-88c7-b6610b0d016c

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View 7-Isobutyl-8-oxo-2-oxa-9-aza-bicyclo[10.2.2]hexadeca-1(15),12(16),13-triene-6,10-dicarboxylic acid 6-hydroxyamide 10-methylcarbamoylmethyl-amide (SL422)'s neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for 7-Isobutyl-8-oxo-2-oxa-9-aza-bicyclo[10.2.2]hexadeca-1(15),12(16),13-triene-6,10-dicarboxylic acid 6-hydroxyamide 10-methylcarbamoylmethyl-amide (SL422).

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with 7-Isobutyl-8-oxo-2-oxa-9-aza-bicyclo[10.2.2]hexadeca-1(15),12(16),13-triene-6,10-dicarboxylic acid 6-hydroxyamide 10-methylcarbamoylmethyl-amide (SL422).

Results found

Linked to

 

Label

Description

 

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG

Knowledge Graph Assertion

A Knowledge Graph Assertion from IDG










  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.